GSK has completed 0 recorded acquisitions and 1 divestiture or spin-off, spanning 2022 to 2022.
| Date | Type | Assets | Counterparty | Value |
|---|---|---|---|---|
| Jul 2022 | Spin-off | Sensodyne, Panadol, Voltaren and Centrum +4 | Haleon | — |
GSK demerged its consumer healthcare business as Haleon, listing it in London and New York in July 2022. The business already contained Pfizer's consumer health portfolio, contributed to a joint venture in 2019, which is how Advil and Centrum came to sit alongside Sensodyne and Panadol.
Ownership recorded here as having ended, whether or not a deal record with a filing behind it exists for the transfer.
| Brand | Owned from | Until | Owner today |
|---|---|---|---|
| Sensodyne | Dec 2000 | Jul 2022 | Haleon |
| Panadol | Dec 2000 | Jul 2022 | Haleon |
| Polident | Dec 2000 | Jul 2022 | Haleon |
| Parodontax | Dec 2000 | Jul 2022 | Haleon |
| Voltaren | Mar 2015 | Jul 2022 | Haleon |
| Otrivin | Mar 2015 | Jul 2022 | Haleon |
| Centrum | Aug 2019 | Jul 2022 | Haleon |
| Advil | Aug 2019 | Jul 2022 | Haleon |